dotinurad + oxaprozin

- This is a **combination** of two drugs: **dotinurad (FYU-981)**, a novel, selective urate reabsorption inhibitor (SURI), and **oxaprozin**, a non-steroidal anti-inflammatory drug (NSAID). - **Dotinurad** acts by selectively inhibiting **urate transporter 1** (URAT1), thereby reducing serum uric acid levels through increasing uric acid excretion[1]. - **Oxaprozin** exerts its effect by inhibiting **cyclooxygenase enzymes (COX-1 and COX-2)**, leading to decreased prostaglandin synthesis, which reduces pain and inflammation[2][3]. - The co-administration aims to leverage the uric acid-lowering effect of dotinurad with the anti-inflammatory and analgesic benefits of oxaprozin, potentially targeting gout or hyperuricemia with comorbid arthritis, though no unique marketed brand exists for this specific combination. - Clinical pharmacokinetic studies show no clinically meaningful drug-drug interactions between dotinurad and oxaprozin[1].

Brand names

COXANTO

Other names

FYU-981 + oxaprozindotinurad + oxaprozinurate transporter 1 inhibitor + oxaprozin